(123-LO) PK Modeling and Simulation using Phoenix WinNonlin
(122-LO) Noncompartmental Data Analysis using Phoenix WinNonlin The courses below are included in the bundle: This bundle includes three courses: two live-online courses, and one certification exam. This bundle is intended for learners who want to learn NCA and PK modeling with an emphasis on the live online format.
“Our bio-simulation software is routinely relied upon to support the development of complex therapies, such as cell and gene therapies, and medicines for much-needed areas, including pediatrics, rare diseases, and COVID-19.(B122-LO) Beginner Modeling Bundle with 1 Examīundle Cost - $750 ($375 Academia, $188 India) Certara continues to support our customers' discovery and drug development efforts during this Pandemic time with scientific informatics, modeling and simulation, and regulatory software tools and platforms to inform, improve and accelerate the process of bringing therapies to patients.Ĭertara works with many biopharmaceutical companies and regulatory agencies to accelerate drug development because our software can be used to test a wide. Certara recognizes the impact COVID-19 is having on our daily personal and business lives.
In addition to using Phoenix WinNonlin and Phoenix NLME, the FDA also uses Certara’s Trial Simulator, IVIVC Toolkit, and PK Submit. PK parameters for tissue/organ were calculated using the sparse ‐sample option available in Phoenix WinNonlin. PK parameters of HCQ were calculated by a noncompartmental method using Phoenix WinNonlin (version 8.0). Further, high cumulative doses of HCQ raise concerns of systemic toxicity, including cardiotoxicity. However, the achievement of lung concentrations predicted to have in vivo antiviral efficacy might not be possible with the currently proposed oral dosing regimens. Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory drug, has been shown to inhibit SARS-COV-2 infection in vitro and tested in clinical studies.
Severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) is a newly identified pathogen causing the coronavirus disease 2019 (COVID-19) pandemic.
Usage of Certara’s Phoenix WinNonlin in COVID StudiesĬertara is providing the drug development community with recent and relevant information regarding COVID-19 and facilitating professional development with on-demand resources.
The integrated tools for data processing, non-compartmental analysis (NCA), PK/PD modeling, post-analysis statistics, table creation, and graphics create an all-in-one collaboration workbench for analysts, reviewers, medical writers, and quality assurance team members. Phoenix WinNonlin is the industry standard for the analysis of pharmacokinetic and pharmacodynamics data. For more information, visit What is Phoenix WinNonlin? Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Certara optimizes R&D productivity, commercial value, and patient outcomes through its unique end-to-end platform of model-informed drug development, regulatory science, and market access solutions.